{"id":488116,"date":"2020-06-03T12:24:01","date_gmt":"2020-06-03T12:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=488116"},"modified":"2020-06-03T12:24:01","modified_gmt":"2020-06-03T12:24:01","slug":"diabetic-peripheral-neuropathy-pipeline-analysis-key-companies-and-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-peripheral-neuropathy-pipeline-analysis-key-companies-and-emerging-therapies_488116.html","title":{"rendered":"Diabetic Peripheral Neuropathy Pipeline Analysis: Key Companies and Emerging Therapies"},"content":{"rendered":"
\"Diabetic<\/a><\/p>\n
\n
Diabetic Peripheral Neuropathy Pipeline <\/p>\n<\/div>\n<\/div>\n<\/div>\n
The most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Gr\u00fcnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies.<\/div>\n

“Diabetic Peripheral Neuropathy Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided, which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the Diabetic Peripheral Neuropathy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Request for Sample pages:<\/strong> https:\/\/www.delveinsight.com\/sample-request\/diabetic-peripheral-neuropathy-pipeline-insight<\/a><\/p>\n

Diabetic Peripheral Neuropathy Pipeline  <\/strong><\/p>\n

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and\/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.<\/p>\n

In the pipeline<\/p>\n

    \n
  1. VM202<\/li>\n
  2. NYX-2925<\/li>\n
  3. WST-057<\/li>\n
  4. Ricolinostat<\/li>\n
  5. ISC 17536<\/li>\n
  6. NRD135S.E1<\/li>\n
  7. Cebranopadol<\/li>\n
  8. GRC 17356<\/li>\n
  9. MEDI7352<\/li>\n
  10. Trazodone\/Gabapentin<\/li>\n<\/ol>\n

    And many others<\/p>\n

    Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202<\/strong> (Helixmith), NYX-2925<\/strong> (Aptinyx), WST-057<\/strong> (4% pirenzepine) WinSanTor, Inc.), Ricolinostat<\/strong> (Regenacy Pharmacuticals), NRD.E1<\/strong> (Novaremed Ltd.), Ebranopadol<\/strong> (Grünenthal GmbH), GRC 17356<\/strong> (Glenmark Pharmaceuticals), and others are also  expected to enter the market by 2030 as effective therapies.<\/p>\n

    The key pharma players working in Diabetic Peripheral Neuropathy Market are:<\/p>\n

      \n
    1. Helixmith,<\/li>\n
    2. Aptinyx<\/li>\n
    3. WinSanTor, Inc<\/li>\n
    4. Regenacy Pharmacuticals<\/li>\n
    5. Ichnos Science<\/li>\n
    6. Novaremed<\/li>\n
    7. Grünenthal GmbH<\/li>\n
    8. Glenmark Pharmaceuticals<\/li>\n
    9. AstraZeneca<\/li>\n
    10. Angelini<\/li>\n<\/ol>\n

      And many others<\/p>\n

       <\/strong><\/p>\n

      Table of Contents <\/strong><\/p>\n

      1. Report Introduction<\/strong><\/p>\n

      2. Diabetic Peripheral Neuropathy <\/strong><\/p>\n

      3. Diabetic Peripheral Neuropathy Current Treatment Patterns<\/strong><\/p>\n

      4. Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective<\/strong><\/p>\n

      5. Therapeutic Assessment<\/strong><\/p>\n

      6. Diabetic Peripheral Neuropathy Late Stage Products (Phase-III)<\/strong><\/p>\n

      7. Diabetic Peripheral Neuropathy Mid Stage Products (Phase-II)<\/strong><\/p>\n

      8. Early Stage Products (Phase-I)<\/strong><\/p>\n

      9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n

      10. Inactive Products<\/strong><\/p>\n

      11. Dormant Products<\/strong><\/p>\n

      12. Diabetic Peripheral Neuropathy Discontinued Products<\/strong><\/p>\n

      13. Diabetic Peripheral Neuropathy Product Profiles<\/strong><\/p>\n

      14. Diabetic Peripheral Neuropathy Key Companies<\/strong><\/p>\n

      15. Diabetic Peripheral Neuropathy Key Products<\/strong><\/p>\n

      16. Dormant and Discontinued Products<\/strong><\/p>\n

      17. Diabetic Peripheral Neuropathy Unmet Needs<\/strong><\/p>\n

      18. Diabetic Peripheral Neuropathy Future Perspectives<\/strong><\/p>\n

      19. Diabetic Peripheral Neuropathy Analyst Review  <\/strong><\/p>\n

      20. Appendix<\/strong><\/p>\n

      21. Report Methodology<\/strong><\/p>\n

       <\/p>\n

       <\/p>\n

      About<\/strong> DelveInsight<\/a><\/p>\n

      DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  <\/p>\n

      Browse through our vast repository<\/a><\/p>\n

       <\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Vinita Rakheja
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Albany
      State:<\/strong> New York
      Country:<\/strong> United States
      Website:<\/strong>       www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      Diabetic Peripheral Neuropathy Pipeline The most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Gr\u00fcnenthal GmbH), GRC 17356 (Glenmark … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,404],"tags":[],"class_list":["post-488116","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/488116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=488116"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/488116\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=488116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=488116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=488116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}